North East and North Cumbria
ICS Formulary
2 Cardiovascular system
02-12 Statins
Atorvastatin
First Choice
10mg, 20mg, 40mg & 80mg tablets
Rosuvastatin
Formulary
5mg, 10mg, 20mg & 40mg tablets
May be used as an alternative to atorvastatin for primary or secondary prevention in line with
NEELI
guidance
Simvastatin
Formulary
10mg, 20mg. 40mg & 80mg tablets
MHRA Drug Safety Update (Dec 2014): Simvastatin: dose limitations with concomitant amlodipine or diltiazem
Atorvastatin Chewable
Formulary
10mg and 20mg chewable tablets
Note:
atorvastatin 10mg and 20mg chewable tablets should be used instead of simvastatin suspension where solid dosage forms cannot be used.
Pravastatin
Formulary
10mg, 20mg & 40mg tablets
Links
Academic Health Science Network (North East and North Cumbria) - Atrial Fibrilation
County Durham and Darlington DVT Pathway Information
County Durham and Tees Valley Prescribing Guideline for the Use of Anticoagulants in Non-Valvular Atrial Fibrillation
MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
MHRA Drug Safety Update (Dec 2014): Simvastatin: dose limitations with concomitant amlodipine or diltiazem
MHRA Drug Safety Update (May 2014): Statins: benefits and risks
NICE NG148: Acute kidney injury: prevention, detection and management
NICE NG185: Acute coronary syndromes
NICE NG191: COVID-19 rapid guideline: managing COVID-19
NICE NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification
NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
North Cumbria - Cardiovascular workplan 2022
Northern England Evaluation and Lipid Intensification (NEELI) Guideline
South Tees Hospitals Cardiology drug prescribing guidelines & formulary
Key
Full Site